Evaluation of potential drug‐drug interaction risk of pexidartinib with substrates of cytochrome P450 and P‐glycoprotein

H Zahir, F Kobayashi, C Zamora… - The Journal of …, 2021 - Wiley Online Library
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
被引用次数：9 相关文章

Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein.

H Zahir, F Kobayashi, C Zamora, R Gajee… - Journal of Clinical …, 2020 - europepmc.org
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …
[HTML] nih.gov

[HTML][HTML] Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

H Zahir, F Kobayashi, C Zamora, R Gajee… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …

Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein

H Zahir, F Kobayashi, C Zamora… - Journal of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …

Evaluation of Potential Drug-Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P-Glycoprotein

H Zahir, F Kobayashi, C Zamora, R Gajee, MS Gordon… - 2020 - repository.arizona.edu
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein.

H Zahir, F Kobayashi, C Zamora… - Journal of Clinical …, 2021 - search.ebscohost.com
Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell
tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 …